We seek to improve the predictive accuracy of the nomogram to predict survival for patients
with castrate mets disease through the addition of pathological data, the results of
automated machine vision based image analysis of H&E stained tumor tissue developed at
Aureon Biosciences,and molecular biomarker studies (25 markers) determined by
immunohistochemistry on tissue microarrays prepared from paraffin-embedded tumor.
Patients in the first retrospective study (Stage 1) must be part of the 409 patient strong
MSKCC cohort with progressive metastatic prostate cancer which was used for the generation
of the original nomogram.
For details please see original publication by Smaletz et al. Patients involved in the
second retrospective study (Stage 2) must be part of the 223 patients with a rising PSA
after surgery or radiation therapy who were treated on conjugate vaccine trials at MSKCC..
For details of excluded patients on the clinical metastases castrate disease study, please
see original publication by Smaletz et al.4
• (MSKCC - add reference if publication available for rising PSA patients)